Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis. Their approach focuses on intra-articular delivery of therapeutic genes for sustained local treatment with minimal systemic side effects. Using adeno-associated virus (AAV) vectors, they are developing and validating new vectors and therapeutic genes, with plans to move […]
uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform. They achieved a landmark approval for their hemophilia B gene therapy, marking a significant advancement in genomic medicine. Building on this success, uniQure is advancing clinical programs for Huntington’s disease and developing a pipeline of preclinical candidates. Orignally spunout as Amsterdam Molecular Therapeutics […]
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies. Their lead candidate, DCP-001, is currently in a Phase 2 study for Acute Myeloid Leukemia (AML), building on promising Phase 1 results. With Orphan Medicinal Product designation in the EU, DCPrime aims to provide effective treatments for hematological cancers, including Multiple […]
Nano-Hybrids
Nano-Hybrids has developed a novel technology that enables the one-step synthesis of a broad range of inorganic/organic core/shell nanoparticles without the use of solvents and additives. This innovative approach enhances efficiency, sustainability, and product purity, making it a significant advancement in nanomaterials. Nano-Hybrids is committed to advancing nanotechnology through sustainable and efficient solutions.
